The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients
Background Wound healing is a known complication associated with sirolimus therapy. Previous studies have demonstrated that obesity is a risk factor for wound‐healing complications (WHC) in patients receiving sirolimus therapy; however, the incidence has not been defined. Methods This is a single‐ce...
Gespeichert in:
Veröffentlicht in: | Clinical transplantation 2013-07, Vol.27 (4), p.E521-E527 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Wound healing is a known complication associated with sirolimus therapy. Previous studies have demonstrated that obesity is a risk factor for wound‐healing complications (WHC) in patients receiving sirolimus therapy; however, the incidence has not been defined.
Methods
This is a single‐center, retrospective cohort study of de novo kidney transplant recipients (KTR) transplanted with a body mass index (BMI) of ≥30 kg/m2 between January 2002 and April 2011 receiving sirolimus vs. sirolimus‐free maintenance immunosuppression.
Results
A total of 317 KTR, 71 sirolimus‐free patients and 246 sirolimus patients, were eligible for inclusion. There was no difference in the primary outcome of WHC within six months of transplant (sirolimus 32.1% vs. sirolimus‐free 29.6%, p = 0.107). Sirolimus exposure was not found to influence WHC (OR 2.906, 95% CI 0.922–9.160); however, BMI Class II (OR 1.830, 95% CI 1.051–3.186) and Class III (OR 3.154, 95% CI 1.484–6.705) were significant predictors of WHC. There was no difference in WHC between the sirolimus group and sirolimus‐free group among patients in obesity Class I (27.3% vs. 15.1%, p = 0.064), Class II (36.6% vs. 34.8%, p = 0.195), or Class III (48.0% vs. 53.3%, p = 0.243).
Conclusion
In our experience, sirolimus does not increase WHC in obese KTR and can be safely used as maintenance immunosuppression immediately following transplant. |
---|---|
ISSN: | 0902-0063 1399-0012 |
DOI: | 10.1111/ctr.12183 |